Chemylix
Company
     Executive summary
     The opportunity
     Our strategy
     Leadership team Technology
     Molecular Foundry™
     Intellectual property
Product
Customers
Investors
Patients
Careers
News
Document center
Contact us
La société
     Profil de l'entreprise
     Opportunité
     Notre stratégie
     Equipe de gouvernance Technologie
     Plateforme de synthèse
     Propriété industrielle
Produit: Chémothèques™
Clients
Investisseurs
Patients
Emplois & carrières
Dernières dépêches
Centre de documentation
Nos coordonnées
The opportunity

An overwhelming need.

The vast and growing drug market is powered by robust fundamentals – strong demand fueled by an aging population of solvent customers increasingly valuing health care.

Patients need and want novel drugs:

- for life-threatening diseases for which there is currently no satisfactory therapy
(heart diseases, cancers, brain diseases, diabetes, orphan diseases)
- to combat against novel infectious agents
(HIV, SARS, West Nile virus, avian flu, etc.)
- for quality-of-life pathologies
(obesity, reproductive function, etc.)
- for currently-met medical needs, because of drug resistance or drug withdrawals
(antibiotics, HIV; arthritis & pain, multiple sclerosis, etc.)

Pharmaceutical companies also need to bring novel medicines to market in order to sustain their growth, as they are losing patent exclusivity on, and revenue from, many of their branded drugs.

Competition
from generics firms is intensifying, and early challenges to still-valid patents are becoming increasingly frequent.
« page 1/3 »
1
Logo